Dynavax Technologies Corp

DYF1

Company Profile

  • Business description

    Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

  • Contact

    2100 Powell Street
    Suite 720
    EmeryvilleCA94608
    USA

    T: +1 510 848-5100

    E: [email protected]

    https://www.dynavax.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    405

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,723.5017.90-0.20%
CAC 407,589.6636.210.48%
DAX 4023,350.55293.171.27%
Dow JONES (US)42,206.8235.160.08%
FTSE 1008,774.6517.15-0.20%
HKSE23,530.48292.741.26%
NASDAQ19,447.4198.86-0.51%
Nikkei 22538,403.2385.11-0.22%
NZX 50 Index12,569.0558.27-0.46%
S&P 5005,967.8413.03-0.22%
S&P/ASX 2008,505.5018.20-0.21%
SSE Composite Index3,359.902.21-0.07%

Market Movers